Health AI Central
Share:
Peer-Reviewed Publication
Clin Cancer Res2026;32(3):562-569.February 4, 2026Journal Article

Automated Imaging as an Adjunct to Serum and Clinical Biomarkers: A New Validated Prediction Tool for Metastatic Castration-Resistant Prostate Cancer.

Michael J Morris1, Jessica Flynn2, Binsheng Zhao3, Aseem Anand4, Karl Sjöstrand4, Steven M Larson3, Ashley M Regazzi1, Gary V Borzillo5, Autumn Park1, Lawrence H Schwartz3, Glenn Heller2
1Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
2Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
3Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
4Exini Diagnostics - a Lantheus Company, Lund, Sweden.
5Johnson and Johnson Innovative Medicine, Spring House, Pennsylvania.
PubMed PMC DOI PDF

Abstract

PURPOSE: Contemporary prostate cancer prognostic models do not include imaging and generally are based on pretreatment parameters. We sought to develop an externally validated model that used novel quantification of soft-tissue and bone disease, integrated with standard clinical and serum biomarkers, at baseline and up to 6 months of treatment. EXPERIMENTAL DESIGN: Two randomized phase 3 trials,…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.